2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, ppt download
Teva recalls US-made drugs following contamination fears - The Boston Globe
Active Biotech's partner Teva starts laquinimod clinical trial
Teva and Active Biotech Announce CONCERTO trial of Laquinimod trial fails
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Teva and Active Biotech Announce Concerto Trial of Laquinimod did not Meet Primary Endpoint | Pharmasources.com
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World
Teva Pharmaceuticals - Wikipedia
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Prostate Cancer Therapeutics Market Competitive Landscape
Active Biotech Regains Rights Over Laquinimod from Teva Pharmaceutical
CHMP says no to Laquinimod
Teva: Leverage A Concern (NYSE:TEVA) | Seeking Alpha
LEGATO-HD Archives
Teva and Active Biotech Expand Investigational MS Treatment Program
Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint - Chemdiv
Active Biotech: Latest News | Tracxn
Teva, Active Biotech enrol first patient in RRMS drug Phase III study - Clinical Trials Arena
Legato-HD Update | Huntington Society of Canada
Teva returns laquinimod global rights to Active Biotech
